Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial.
J Clin Endocrinol Metab. 2016 Feb;101(2):533-8. doi: 10.1210/jc.2015-3599. Epub 2015 Dec 14.
Konijeti GG1, Arora P1, Boylan MR1, Song Y1, Huang S1, Harrell F1, Newton-Cheh C1, O'Neill D1, Korzenik J1, Wang TJ1, Chan AT1.
- Covid-19, T cells, and Vitamin D
- T-cells increased with monthly doses of 140,000 IU vitamin D – April 2014
- Autoimmune diseases and over-active T cells (which are deactivated by vitamin D) – March 2014
- The vitamin D receptor and T cell function – June 2013
- Autoimmunity, T Cells and vitamin D: A chemical network analysis – May 2013
- Vitamin D helps T-cell and immune system – overview Aug 2011
- Fight Cancer with more than cut, burn, and poison – Nobel prize for T-Cell – Oct 2018
- Vitamin D associated with reduced T-cell attacks in Multiple Sclerosis – Sept 2012
- Vitamin D-binding protein controls T cell responses to vitamin D in the lab – Sept 2014
- Search for treg OR "t-cell" in VitaminDWiki 1860 items as of July 2020
Immunity category starts with
see alsoVirus category listing has
Overview Influenza and vitamin D
Search for treg OR "t-cell" in VitaminDWiki 1440 items as of Jan 2020
Search VitaminDWik for INFECTION in title 50 items as of Aug 2019
Search VitaminDWik for BACTERIA in title 25 items as of Aug 2019
Vitamin D and the Immune System – chapter Aug 2019
7X less risk of influenza if Vitamin D levels higher than 30 ng – Oct 2017
Common cold prevented and treated by Vitamin D, Vitamin C, Zinc, and Echinacea – review April 2018
Vitamin D improves T Cell immunity – RCT Feb 2016
Vitamin D Every Day to Keep the Infection Away 2015 file
shows increasing publications on vitamin D and Infection
CONTEXT: Although studies have linked vitamin D deficiency with immune-mediated diseases, data demonstrating a direct effect on T-cell function are sparse.
OBJECTIVE: Our objective was to determine whether oral vitamin D3 influences T-cell activation in humans with vitamin D deficiency.
DESIGN: This was a single-center ancillary study within Vitamin D Therapy in Individuals at High Risk of Hypertension, a double-blind, multicenter, randomized controlled trial.
SETTING: This study was undertaken in a single academic medical center.
PARTICIPANTS: Adults with vitamin D deficiency and untreated pre- or early stage I hypertension were included.
In Vitamin D Therapy in Individuals at High Risk of Hypertension, participants were randomized to either low- (400 IU daily) or high- (4000 IU daily) dose oral vitamin D3 for 6 months. In this ancillary study of 38 patients, we measured CD4+ T-cell activation estimated by intracellular ATP release after stimulation of whole blood with plant lectin phytohemagglutinin collected at baseline (pretreatment) and 2-month follow-up.
MAIN OUTCOME MEASURE:
Determining whether ATP level changes were significantly different between treatment groups was the main outcome measure.
Treatment with 4000 IU of vitamin D3 decreased intracellular CD4+ ATP release by 95.5 ng/ml (interquartile range, -219.5 to 105.8). In contrast, 400 IU of vitamin D3 decreased intracellular CD4+ ATP release by 0.5 ng/ml (interquartile range, -69.2 to 148.5). In a proportional odds model, high-dose vitamin D3 was more likely than low-dose vitamin D3 to decrease CD4+ ATP release (odds ratio, 3.43; 95% confidence interval, 1.06-1.11).
In this ancillary study of a randomized controlled trial, we found that high-dose vitamin D3 significantly reduced CD4+ T-cell activation compared to low-dose vitamin D3, providing human evidence that vitamin D can influence cell-mediated immunity.
PMID: 26653112 PMCID: PMC4880125 DOI: 10.1210/jc.2015-3599